JP6163105B2 - 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤 - Google Patents

体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤 Download PDF

Info

Publication number
JP6163105B2
JP6163105B2 JP2013539987A JP2013539987A JP6163105B2 JP 6163105 B2 JP6163105 B2 JP 6163105B2 JP 2013539987 A JP2013539987 A JP 2013539987A JP 2013539987 A JP2013539987 A JP 2013539987A JP 6163105 B2 JP6163105 B2 JP 6163105B2
Authority
JP
Japan
Prior art keywords
catenin
cbp
alkyl
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013539987A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013542999A5 (cg-RX-API-DMAC7.html
JP2013542999A (ja
Inventor
マイケル カン，
マイケル カン，
ジア−リン テオ，
ジア−リン テオ，
マイケル マクミラン，
マイケル マクミラン，
イー ザオ，
イー ザオ，
ヨンフェン ウー，
ヨンフェン ウー，
Original Assignee
ユニバーシティー オブ サザン カリフォルニア
ユニバーシティー オブ サザン カリフォルニア
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ サザン カリフォルニア, ユニバーシティー オブ サザン カリフォルニア filed Critical ユニバーシティー オブ サザン カリフォルニア
Publication of JP2013542999A publication Critical patent/JP2013542999A/ja
Publication of JP2013542999A5 publication Critical patent/JP2013542999A5/ja
Application granted granted Critical
Publication of JP6163105B2 publication Critical patent/JP6163105B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
JP2013539987A 2010-11-16 2011-11-16 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤 Active JP6163105B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US41434810P 2010-11-16 2010-11-16
US41433410P 2010-11-16 2010-11-16
US61/414,334 2010-11-16
US61/414,348 2010-11-16
US201161545033P 2011-10-07 2011-10-07
US61/545,033 2011-10-07
PCT/US2011/061062 WO2012068299A2 (en) 2010-11-16 2011-11-16 Cbp/catenin antagonists for enhancing asymmetric division of somatic stem cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017036705A Division JP6518706B2 (ja) 2010-11-16 2017-02-28 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤

Publications (3)

Publication Number Publication Date
JP2013542999A JP2013542999A (ja) 2013-11-28
JP2013542999A5 JP2013542999A5 (cg-RX-API-DMAC7.html) 2015-01-15
JP6163105B2 true JP6163105B2 (ja) 2017-07-12

Family

ID=46084627

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2013539987A Active JP6163105B2 (ja) 2010-11-16 2011-11-16 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤
JP2017036705A Active JP6518706B2 (ja) 2010-11-16 2017-02-28 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017036705A Active JP6518706B2 (ja) 2010-11-16 2017-02-28 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤

Country Status (10)

Country Link
US (1) US10092568B2 (cg-RX-API-DMAC7.html)
EP (1) EP2640393B1 (cg-RX-API-DMAC7.html)
JP (2) JP6163105B2 (cg-RX-API-DMAC7.html)
KR (1) KR102077871B1 (cg-RX-API-DMAC7.html)
CN (1) CN103476415B (cg-RX-API-DMAC7.html)
AU (2) AU2011329854B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013012228B1 (cg-RX-API-DMAC7.html)
CA (1) CA2817975C (cg-RX-API-DMAC7.html)
ES (1) ES2935544T3 (cg-RX-API-DMAC7.html)
WO (1) WO2012068299A2 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017088633A (ja) * 2010-11-16 2017-05-25 ユニバーシティー オブ サザン カリフォルニア 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9371330B2 (en) 2010-11-16 2016-06-21 University Of Southern California Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
US20160074400A1 (en) * 2012-08-06 2016-03-17 University Of Southern California Wnt modulators for the protection, mitigation and treatment of radiation injury
CN104902902A (zh) * 2012-10-19 2015-09-09 株式会社棱镜制药 使用cbp/连环蛋白的抑制剂治疗硬皮病
AU2013332733A1 (en) * 2012-10-19 2015-06-04 Prism Pharma Co., Ltd. Treatment of hyperproliferative and pre-cancerous skin diseases using an inhibitor of CBP/catenin
US20160166577A1 (en) * 2012-10-19 2016-06-16 Prism Pharma Co., Ltd. Treatment of pulmonary fibrosis using an inhibitor of cbp/catenin
AU2013332731A1 (en) * 2012-10-19 2015-06-04 Prism Pharma Co., Ltd. Methods for treating eye disorders
WO2014061823A1 (en) * 2012-10-19 2014-04-24 Hiroyuki Kouji Method for treating type i and type ii diabetes
CN104902900A (zh) * 2012-10-19 2015-09-09 株式会社棱镜制药 使用cbp/连环蛋白的抑制剂治疗病毒性和传染性疾病
PL3003473T3 (pl) 2013-05-30 2019-05-31 Neurostim Solutions LLC Miejscowa stymulacja neurologiczna
US11229789B2 (en) 2013-05-30 2022-01-25 Neurostim Oab, Inc. Neuro activator with controller
CN104231048B (zh) * 2013-06-05 2017-05-24 财团法人工业技术研究院 生发胜肽及药物组合物
WO2015157771A1 (en) * 2014-04-11 2015-10-15 Bcs Business Consulting Services Pte Ltd Hair enhancing formulation
RU2549987C1 (ru) * 2014-06-17 2015-05-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Средство для ускорения заживления ран и регенерации тканей
US11077301B2 (en) 2015-02-21 2021-08-03 NeurostimOAB, Inc. Topical nerve stimulator and sensor for bladder control
WO2017025963A1 (en) * 2015-08-10 2017-02-16 The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center Methods and pharmaceutical compositions for improving wound healing using cd24
WO2017044302A1 (en) * 2015-09-09 2017-03-16 Rush University Medical Center Compositions and methods for treating bone diseases
US10597398B2 (en) * 2015-09-18 2020-03-24 National University Corporation Tottori University Suppression and regeneration promoting effect of low molecular weight compound on cancer and fibrosis
EP3320901B1 (en) * 2016-01-28 2020-03-04 Accendatech Dimethylaminomicheliolide for use in the treatment of pulmonary fibrosis
CN105854018B (zh) * 2016-03-28 2018-11-13 杭州师范大学 Wnt抑制剂在制备治疗造血再生障碍性疾病药物中的应用
WO2017184808A1 (en) * 2016-04-20 2017-10-26 University Of Southern California Compounds and methods for increasing hematopoiesis
EP3655961A4 (en) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology HEALTHY AND SICK BARRIER TISSUE CELL ATLAS
WO2019094365A1 (en) 2017-11-07 2019-05-16 Neurostim Oab, Inc. Non-invasive nerve activator with adaptive circuit
JP7605576B2 (ja) 2018-07-25 2024-12-24 ポーラ化成工業株式会社 皮膚老化改善剤のスクリーニング方法
KR20220025834A (ko) 2019-06-26 2022-03-03 뉴로스팀 테크놀로지스 엘엘씨 적응적 회로를 갖는 비침습적 신경 활성화기
JP2023506713A (ja) 2019-12-16 2023-02-20 ニューロスティム テクノロジーズ エルエルシー 昇圧電荷送達を用いた非侵襲性神経アクティベータ
KR102612610B1 (ko) * 2020-02-07 2023-12-12 주식회사 한스파마 신경줄기세포의 제조방법 및 이로부터 얻어진 신경줄기세포 배양액을 유효성분으로 포함하는 피부 재생, 항산화, 항염증 및 상처 치료용 조성물
US12486275B2 (en) 2020-03-12 2025-12-02 City Of Hope Substituted pyrazino[2,1-c][1,2,4]triazines as Wnt/CBP/catenin signaling pathway inhibitors
CA3194606A1 (en) * 2020-10-05 2022-04-14 Fuqiang Ruan Topical agents for dermatological applications
CN117083065A (zh) * 2020-10-30 2023-11-17 庆应义塾 肌肉减少症相关疾病等的新颖治疗和预防
WO2023114456A1 (en) * 2021-12-17 2023-06-22 Athira Pharma, Inc. Uses of bicyclic compounds for the treatment of diseases
JP7178143B1 (ja) 2022-03-17 2022-11-25 学校法人関西医科大学 爪幹細胞及び毛髪の成長を助長する外用剤
AU2023366929A1 (en) 2022-10-25 2025-05-08 Veradermics, Incorporated Compositions and methods of use for modified release minoxidil

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0267878A1 (en) 1986-11-14 1988-05-18 Ciba-Geigy Ag N9-cyclopentyl-substituted adenine derivatives
US5262321A (en) 1991-05-31 1993-11-16 Dana-Farber Cancer Institute DNA encoding p107 tumor suppressor
US5750336A (en) 1994-02-10 1998-05-12 The Salk Institute For Biological Studies Assays for the identification of compounds which inhibit activation of cAMP and mitogen responsive genes
US5658784A (en) 1994-04-14 1997-08-19 Dana-Farber Cancer Institute, Inc. Nucleic acid encoding transcription factor p300 and uses of p300
IT1271007B (it) 1994-09-13 1997-05-26 Zambon Spa Derivati del 2-ammino-1,2,3,4-tetraidronaftalene attivi sul sistema cardiovascolare
US6184223B1 (en) 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
WO1999037753A1 (en) 1998-01-23 1999-07-29 Newbiotics, Inc. Enzyme catalyzed therapeutic agents
EP2308863A1 (en) 2000-05-15 2011-04-13 Paratek Pharmaceuticals, Inc. 7-substituted fused ring tetracycline compounds
CN1333270A (zh) * 2000-07-07 2002-01-30 上海博德基因开发有限公司 一种新的多肽——人cbp20蛋白47.74和编码这种多肽的多核苷酸
US7671054B1 (en) 2001-10-12 2010-03-02 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US20040072831A1 (en) 2001-10-12 2004-04-15 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7566711B2 (en) 2001-10-12 2009-07-28 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7232822B2 (en) 2001-10-12 2007-06-19 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
TW200304371A (en) 2002-02-22 2003-10-01 Akzo Nobel Nv Substituted 10-ary1-11H-benzo [b] fluorenes and 7-ary1-5, 6-dihydro-benz [a] anthracenes for selective effects on estrogen receptors
US6762185B1 (en) * 2002-03-01 2004-07-13 Choongwae Pharma Corporation Compounds useful for treatment of cancer, compositions containing the same, and methods of their use
WO2004035587A1 (en) 2002-10-17 2004-04-29 Myriad Genetics, Inc. Reverse-turn mimetics and composition and methods relating thereto
AU2004268647B2 (en) 2003-08-28 2010-07-01 Choongwae Pharma Corporation Modulation of beta-catenin/TCF activated transcription
JP3722146B1 (ja) 2004-06-16 2005-11-30 セイコーエプソン株式会社 プロジェクタおよび画像補正方法
US7998930B2 (en) 2004-11-04 2011-08-16 Hanall Biopharma Co., Ltd. Modified growth hormones
US7563825B1 (en) 2005-03-18 2009-07-21 Choongwae Pharma Corporation Modulation of beta-catenin coactivator interactions to effect stem cell growth or differentiation
AU2006227776A1 (en) * 2005-03-18 2006-09-28 Institute For Chemical Genomics Alpha-helix mimetics and methods relating to the treatment of fibrosis
US20080009500A1 (en) 2005-11-08 2008-01-10 Michael Kahn Alpha-helix mimetics and methods relating to the treatment of fibrotic disorders
ATE446509T1 (de) * 2005-11-28 2009-11-15 Choongwae Pharma Corp Serumfreie expansion von zellen in kultur
EP2029142A4 (en) 2006-05-30 2010-06-16 Choongwae Pharma Corp COMPOSITION FOR INDUCTION OR INHIBITION OF STEM CELL PROLIFERATION
KR20090060334A (ko) 2006-09-08 2009-06-11 제넨테크, 인크. Ｗｎｔ 길항제 및 ｗｎｔ-매개 장애의 진단 및 치료에서의 이의 용도
CN101130799A (zh) * 2007-08-06 2008-02-27 大连理工大学 利用几丁质生产生物能源物质的方法
WO2010044485A1 (en) 2008-10-14 2010-04-22 Prism Biolab Corporation Alpha helix mimetics in the treatment of cancer
WO2010124365A1 (en) * 2009-04-27 2010-11-04 Ottawa Hospital Research Institute Compositions and methods for modulating stem cells and uses thereof
US9040531B2 (en) 2009-05-07 2015-05-26 Prism BioLab Co., Ltd. Alpha helix mimetics and methods relating thereto
AU2011329854B2 (en) 2010-11-16 2017-03-30 University Of Southern California CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
EP2678341A1 (en) * 2011-02-25 2014-01-01 PRISM Pharma Co., Ltd. Alpha helix mimetics and methods relating thereto

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017088633A (ja) * 2010-11-16 2017-05-25 ユニバーシティー オブ サザン カリフォルニア 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤

Also Published As

Publication number Publication date
AU2017201750B2 (en) 2019-01-17
AU2011329854A1 (en) 2013-07-04
BR112013012228B1 (pt) 2023-02-28
JP6518706B2 (ja) 2019-05-22
CA2817975C (en) 2020-03-31
JP2017088633A (ja) 2017-05-25
WO2012068299A2 (en) 2012-05-24
US20130280233A1 (en) 2013-10-24
AU2017201750A1 (en) 2017-03-30
CA2817975A1 (en) 2012-05-24
US10092568B2 (en) 2018-10-09
EP2640393A2 (en) 2013-09-25
EP2640393B1 (en) 2022-10-12
CN103476415A (zh) 2013-12-25
AU2017201750B9 (en) 2019-01-31
EP2640393A4 (en) 2015-05-27
ES2935544T3 (es) 2023-03-07
KR102077871B1 (ko) 2020-02-14
KR20130140079A (ko) 2013-12-23
WO2012068299A9 (en) 2013-06-20
AU2011329854B2 (en) 2017-03-30
CN103476415B (zh) 2017-09-22
BR112013012228A2 (pt) 2021-05-18
JP2013542999A (ja) 2013-11-28

Similar Documents

Publication Publication Date Title
JP6163105B2 (ja) 体性幹細胞の非対称分裂を促進するためのｃｂｐ／カテニン拮抗剤
US9371330B2 (en) Substituted pyrazino[1,2-a]pyrimidines useful as CBP/catenin antagonists for enhancing asymmetric division of somatic stem cells
Bergholz et al. Role of p63 in development, tumorigenesis and cancer progression
CN105687185B (zh) 使用奈福泮化合物治疗侵袭型纤维瘤病和β-联蛋白介导的疾病的方法
TW202126631A (zh) 作為klk5/7雙重抑制劑之苯并酮化合物
KR20230068277A (ko) 노화세포 제거용 화합물 및 이의 용도
KR102168006B1 (ko) 체세포 줄기 세포의 비대칭 분열을 향상시키기 위한 ｃｂｐ/카테닌 길항제
JP2016214085A (ja) 毛成長抑制剤の評価又は選択方法
Perbal 10th international workshop on the CCN family of genes, Niagara Falls, Canada, October 21–24, 2019
Kass Youssef et al. Epithelial-mesenchymal transition in tissue repair and degeneration
Chelladurai et al. A heterodimer of hemoglobin identifies theranostic targets on brain‐metastasizing melanoma cells
Yu et al. Induced pluripotent stem cell-derived conditioned medium, as well as nintedanib, ameliorates bleomycin-induced pulmonary fibrosis via suppressing endothelial-mesenchymal transition
TWI530285B (zh) A method for promoting hair growth and a composition for use thereof
Russo Structural and functional consequences of p63 mutations causative of AEC syndrome
KR20210069787A (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20141117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150914

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20151209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160210

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161124

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170228

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170601

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170616

R150 Certificate of patent or registration of utility model

Ref document number: 6163105

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250